Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mavenclad Poised To Be Big Mover For Merck KGaA

Executive Summary

The German group is predicting sales of its new MS drug Mavenclad in the mid-triple digit million euro range worldwide in 2019 if all goes well across the Atlantic.

Advertisement

Related Content

Merck KGaA Expects Core Franchises, Alliances To Strengthen In China
Keytruda/Inlyta Data Stoke Competition In Kidney Cancer
Pfizer Well-Placed To Lead First-Line Advanced RCC Market
Merck of Germany's Hunt For MS BTKi Partner Boosted By Evobrutinib Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124872

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel